Ulla Engotröm

Title: Ulla Engström: Innovator in Cancer Research

Introduction

Ulla Engström is a prominent inventor based in Uppsala, Sweden. She has made significant contributions to the field of cancer research, particularly through her innovative work on the Smad2 protein. Her research focuses on the mechanisms of phosphorylation and the interactions of Smad proteins, which are crucial in understanding cancer pathways.

Latest Patents

Ulla Engström holds a patent titled "Smad2 phosphorylation and interaction with Smad4." This invention describes the amino acid residues of the Smad2 protein that are important for its phosphorylation and activity. It includes Smad2 polypeptide fragments and biologically functional variants, including dominant-negative variants of Smad2 and related antibodies. The patent also covers nucleic acids that encode such variants and methods for utilizing these nucleic acids and polypeptides in research and therapeutic applications.

Career Highlights

Engström is affiliated with the Ludwig Institute for Cancer Research Limited, where she continues to advance her research in cancer biology. Her work has been instrumental in elucidating the roles of Smad proteins in cellular signaling pathways, which has implications for cancer treatment and understanding tumor biology.

Collaborations

Ulla Engström has collaborated with notable researchers in her field, including Ester Piek and Kiyoshi Tamaki. These collaborations have enhanced her research and contributed to the broader scientific community's understanding of cancer mechanisms.

Conclusion

Ulla Engström's innovative work and patent contributions significantly impact cancer research. Her dedication to understanding the Smad2 protein and its interactions paves the way for future advancements in cancer therapies.